Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
05:49am, Saturday, 28'th Jun 2025
I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
06:46pm, Friday, 27'th Jun 2025
AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
11:11am, Friday, 27'th Jun 2025
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
Jim Cramer's Safest Stock For Retirees
02:54pm, Thursday, 26'th Jun 2025
Jim Cramer has a mixed record when it comes to choosing stocks.
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
10:56am, Thursday, 26'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
08:58am, Wednesday, 25'th Jun 2025
The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in em
My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys
08:10am, Wednesday, 25'th Jun 2025
Markets remained volatile in May 2025 amid ongoing trade tensions and mixed signals from Washington and Wall Street. While U.S.-China talks quietly resumed, tariffs persisted and business sentiment st
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:00am, Tuesday, 24'th Jun 2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
09:25am, Tuesday, 24'th Jun 2025
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
08:00am, Tuesday, 24'th Jun 2025
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di
3 dividend stocks investors can look for stability as Iran attacks US base in Qatar
03:05pm, Monday, 23'rd Jun 2025
US stocks could see pressure this week after Iran struck US bases in Qatar in retaliation for President Trump's airstrike on Tehran's nuclear facilities. Amidst the geopolitical backdrop that seems to
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
10:31am, Friday, 20'th Jun 2025
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
I'm Buying Dividend Giants At Huge Discounts
09:00am, Friday, 20'th Jun 2025
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o
AbbVie Declares Quarterly Dividend
08:00am, Friday, 20'th Jun 2025
NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
AbbVie's migraine drug meets main goal of late-stage study
07:27am, Wednesday, 18'th Jun 2025
AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.
